Alimera Sciences Competitors and Similar CompaniesClear all
Alimera Sciences's competitors and similar companies include BeyondSpring, Biogen and Genentech.
 Alimera Sciences Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. |  BeyondSpring BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. | |
Founding Date | Founding Date 2003 | Founding Date 2010 | Founding Date 1978 | Founding Date 1976 |
Type | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Alpharetta, US HQ Berlin, DE Dublin 2, IE Lisboa, PT Hampshire, GB | Locations Florham Park, US HQ | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more |
Employees | Employees 1222% decrease | Employees 4014% increase | Employees 7,605 | Employees 18,077 |
Valuation ($) | Valuation ($) 301.3 m | Valuation ($) 89.4 m | Valuation ($) 26.7 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $80.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) N/A |
Gross profit | Gross profit $69.9m (FY, 2023) | Gross profit N/A | Gross profit $7.5b (FY, 2025) | Gross profit N/A |
Net income | Net income ($20.1m) (FY, 2023) | Net income ($16.7m) (FY, 2024) | Net income $1.3b (FY, 2025) | Net income N/A |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2019) | Phase I Trials Products 4 (FY, 2024) | Phase I Trials Products 28 (Jul, 2025) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2017) | Phase II Trials Products 6 (FY, 2024) | Phase II Trials Products 19 (Jul, 2025) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2019) | Phase III Trials Products 11 (FY, 2024) | Phase III Trials Products 41 (Jul, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 232.6m | Total funding raised $ 36.1m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
BeyondSpring
HQ
Florham Park, US
Employees
40↑ 14% increase
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View companyGenentech
HQ
South San Francisco, US
Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
View company